Results 181 to 190 of about 84,892 (241)

Molecular characterization of Human T-cell Lymphotropic Viruses 1 and 2 (HTLV-1 and HTLV-2) in samples from blood donation candidates in the state of Pará, Brazilian Amazon. [PDF]

Braz J Infect Dis
Maneschy CA, Lobo PS, Amaral CEM, Dos Santos Barile KA, de Castro JAA, Silvestre RVD, Freitas FB, Soares LS, Guerra SFS.   +8 more
europepmc   +1 more source

Transcriptomic and Epitranscriptomic Landscape of Integrated HTLV-1 in MT2 Cells. [PDF]

Viruses
Wei S, Zhang B, Han J, Li H, Liu Y, Jia L, Li J, Huang X, Li L.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

human T-lymphotropic virus 1

CABI Compendium, 2022
This datasheet on human T-lymphotropic virus 1 covers Identity, Distribution, Hosts/Species Affected.
F. Bravo, K. Verdonck
semanticscholar   +2 more sources

Human T‐lymphotropic Virus 1 (HTLV‐1) infection – dermatological implications

International Journal of Dermatology, 2011
AbstractHuman T‐lymphotropic virus type 1 (HTLV‐1) is a type C retrovirus primarily endemic to Japan, Central and South America, the Middle East, regions of Africa, and the Caribbean. Currently, an estimated 10–20 million people worldwide are infected with this virus.
M. Amano, M. Setoyama, A. Grant, F. Kerdel   +3 more
semanticscholar   +3 more sources

Human T lymphotropic virus‐1 infection

Australasian Journal of Dermatology, 1996
SUMMARYHuman T lymphotropic virus‐1 (HTLV‐1) is a retrovirus which infects T lymphocytes (CD4+) to cause adult T cell leukaemia/lymphoma (ATL), tropical spastic paraparesis and several other HTLV‐1 associated disorders. ATL has been reported worldwide but areas of high incidence include Japan (particularly the south‐west), Central and South America ...
T. Kanzaki, M. Setoyama, Y. Katahira
semanticscholar   +3 more sources

Human T-lymphotropic virus 1 neurologic disease

Current Treatment Options in Neurology, 2008
Human T-lymphotrophic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a disabling myelopathy, but clinical trials of specific drugs to treat it are lacking. There are many reasons for the absence of specific therapeutic studies, including difficulty in enrolling patients, inadequate measurement tools to evaluate ...
A. Araujo, M. Lima, M. T. Silva
semanticscholar   +3 more sources

Human T-lymphotropic virus 1: recent knowledge about an ancient infection.

The Lancet Infectious Diseases, 2007
Human T-lymphotropic virus 1 (HTLV-1) has infected human beings for thousands of years, but knowledge about the infection and its pathogenesis is only recently emerging. The virus can be transmitted from mother to child, through sexual contact, and through contaminated blood products.
K. Verdonck, E. González, S. Van Dooren, A. Vandamme, G. Vanham, E. Gotuzzo   +5 more
semanticscholar   +4 more sources

Human T‐lymphotropic virus 1 (HTLV‐1) pathogenesis: A systems virology study

Journal of Cellular Biochemistry, 2018
AbstractThe main mechanisms of interaction between Human T‐lymphotropic virus type 1 (HTLV‐1) and its hosts in the manifestation of the related disease including HTLV‐1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and Adult T‐cell leukemia/lymphoma (ATLL) are yet to be determined.
Sayed-Hamidreza Mozhgani, M. Zarei-Ghobadi, Majid Teymoori-Rad, T. Mokhtari-azad, M. Mirzaie, M. Sheikhi, S. Jazayeri, Ramin Shahbahrami, H. Ghourchian, Mohieddin Jafari, S. Rezaee, M. Norouzi   +11 more
semanticscholar   +3 more sources

15 – Human T-lymphotropic Virus 1

, 2017
Francisco G. Bravo
semanticscholar   +2 more sources